Under a tenth of patients who could benefit from GLP-1 drugs such as Wegovy are able to get them, warns the World Health Organization as it issues its first guidance on the medications.
With in excess of 1,000,000,000 people worldwide currently classified as obese, it is calling for more widespread and fairer availability to these injectable treatments.
Based on forecasts, more than two billion are projected to be obese by 2030 unless action is taken.
"The new guidelines affirms that excess weight is a long-term condition that can be addressed with thorough and continuous treatment," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, limited production capacity, and distribution challenges are significant barriers to broad availability to the injections that can assist patients in reducing considerable body mass, notes the organization.
Weight-Loss Drug Scarcity
Even under the current best projected case, the supply of these medications would only suffice for about 100 million people – fewer than 10% of the global need, according to the WHO.
The guideline encourages nations and manufacturers to widen availability, through strategies including patent sharing.
Exclusive production rights on the active ingredient – the core ingredient of the drug Wegovy – is scheduled to end in multiple nations in 2026.
The Way Obesity Injections Function
The injections imitate a body's own hormone to delay gastric emptying, reduce hunger and increase feelings of fullness so individuals reduce food intake.
People usually begin shedding pounds in the initial weeks of beginning the regular doses.
Research suggests patients may put most of the weight back on a year later of halting the treatment, as their typical hunger come back.
To be carrying excess weight raises your risk for developing diseases, including diabetes, heart disease, stroke, and certain malignancies.
Obesity impacts individuals in every country and was responsible for millions of deaths worldwide in 2024, according to the health agency.
